Supplementary data

Supplementary Table 1: Inclusion and Exclusion criteria:

Inclusion criteria

Informed consent obtained before any trial-related activities. Trial-related activities are any procedures that are carried out as part of the trial, including activities to determine suitability for the trial

Type 2 diabetes

Male or female ≥18 years of age

HbA_{1c} 7.0–9.0% (53–75 mmol/mol) (both inclusive)

Treatment with daily GLP-1RA at maximum dose according to local label (i.e. 1.8 mg once-daily liraglutide or 10 microgram twice-daily exenatide) or documented maximum tolerated dose (i.e. 1.2 mg OD liraglutide or 5 microgram BID exenatide) in combination with a stable daily dose of metformin (≥1500 mg or documented maximum tolerated dose) ± stable daily dose of pioglitazone (≥30 mg) ± stable daily dose of sulfonylurea (≥half of the max approved dose according to local label) ≥90 days prior to screening visit.

Body mass index ≤40 kg/m²

Able and willing to adhere to the protocol including performing self-monitored plasma glucose profiles, to keep a trial diary and to use pre-filled pen device

Exclusion criteria

Known or suspected hypersensitivity to trial product(s) or related products

Previous participation in this trial. Participation is defined as randomization

Females of child-bearing potential who are pregnant, breast-feeding or intend to become pregnant or are not using adequate contraceptive methods (adequate contraceptive measures as required by local law or practice)

Receipt of any investigational medicinal product within 30 days prior to screening visit (Visit 1) Use of any drug (except metformin, pioglitazone, sulfonylurea and GLP-1RA)

which in the investigator's opinion could interfere with the blood glucose level (e.g. systemic corticosteroids).

Treatment with any insulin regimen (short term treatment due to intercurrent illness including gestational diabetes is allowed at the discretion of the investigator)

Impaired liver function, defined as alanine aminotransferase (ALAT) ≥2.5 times upper normal range (UNR)

Impaired renal function defined as serum-creatinine \geq 133 µmol/L (1.5 mg/dL) for males and \geq 125 µmol/L (1.4 mg/dL) for females, or as allowed according to local contraindications for metformin

Screening calcitonin ≥50 ng/L

Personal or family history of medullary thyroid carcinoma (MTC) or multiple endocrine neoplasia type 2 (MEN2)

Cardiovascular disorders defined as; congestive heart failure (New York Heart Association (NYHA) class III-IV), diagnosis of unstable angina pectoris, cerebral stroke and/or myocardial infarction within the past 52 weeks prior to Visit 1 and/or planned coronary, carotid or peripheral artery revascularisation procedures

Severe uncontrolled treated or untreated hypertension (systolic blood pressure ≥180 mm Hg or diastolic blood pressure ≥100 mm Hg)

Proliferative retinopathy requiring acute treatment or maculopathy (macular edema) according to the investigator's opinion

Subjects with a clinical significant, active (during the past 12 months) disease of the gastrointestinal, pulmonary, endocrinological (except for the type 2 diabetes),

neurological, genitourinary or haematological system that in the opinion of the Investigator,

may confound the results of the trial or pose additional risk in administering trial product

Mental incapacity, unwillingness or language barrier precluding adequate understanding of the trial procedures or cooperation with the trial personnel

Known or suspected abuse of prescription drugs, alcohol or illicit substances


History of chronic pancreatitis or idiopathic acute pancreatitis

Suffer from a life threatening disease including malignant neoplasms and medical history of malignant neoplasms within the last 5 years (except basal and squamous cell skin cancer)

Supplementary Table 2: Titration algorithm

Fasting plas	Dose adjustment		
mmol/L	mmol/L mg/dL		
<4.0	<72	-2	
4.0–5.0	72–90	0	
>5.0	>90	+2	

Supplementary Figure 1: Patient disposition. FAS, full analysis set; GLP-1RA, glucagon-like peptide-1 receptor agonist; IDegLira, insulin degludec/liraglutide combination; SAS, safety analysis set.



Supplementary Table 3: Hypoglycemia

	IDegLira n = 291			Unchang <i>n</i> = 145	ed GLP-1RA	Estimated rate ratio	
	N (%)	Events	Rate	N (%)	Events	Rate	[95% CI]
Severe	1 (0.3)	1	0.007	0 (0)	0	0	N/A
Confirmed	93 (32)	397	2.82	4 (2.8)	8	0.12	25.36 [10.6; 60.5], <i>p</i> < 0.001
Nocturnal confirmed	32 (11)	64	0.45	1 (0.7)	1	0.015	32.82 [4.13; 261.04], <i>p</i> < 0.001

N, number of subjects with \geq 1 event; %, percentage of subjects; rate, unadjusted event rate (episodes

per patient-year of exposure). Data are based on the SAS. Estimated rate ratio based on FAS. FAS,

full analysis set; GLP-1RA, glucagon-like peptide-1 receptor agonist; IDegLira, insulin

degludec/liraglutide combination; PYE, patient years of exposure; SAS, safety analysis set.

	IDegLira + met ± pio n = 223		Unchanged GLP- 1RA + met ± pio <i>n</i> = 111		IDegLira + met + SU ± pio <i>n</i> = 68			Unchanged GLP- 1RA + met + SU \pm pio $n = 34$				
	N (%)	Even ts	Rate	N (%)	Even ts	Rate	N (%)	Even ts	Rate	N (%)	Even ts	Rate
Severe	1 (0.4)	1	0.009	0 (0)	0	0	0 (0)	0	0	0 (0)	0	0
Confirmed	62 (28)	189	1.75	0 (0)	0	0	31 (46)	208	6.34	4 (12)	8	0.51

Supplementary Table 4: Hypoglycemia by pre-trial oral anti-diabetic drugs

N, number of subjects with ≥1 event; %, percentage of subjects; rate, unadjusted event rate (episodes per patient-year of exposure). Data are based on the SAS. Met, metformin, GLP-1RA, glucagon-like peptide-1 receptor agonist; IDegLira, insulin degludec/liraglutide combination; pio, pioglitazone; PYE, patient years of exposure; SAS; safety analysis set; SU, sulfonylurea.

Supplementary Table 5: Lipase and amylase by treatment week

	IDegLira n = 290	Unchanged GLP-1RA n = 145
Lipase, U/	Ĺ	
Week 0	61.9 (44.3) [17.0; 388.0]	57.3 (37.4) [17.0; 335.0]
Week 12	68.0 (55.6) [14.0; 438.0]	60.8 (39.7) [18.0; 286.0]
Week 26	60.9 (40.1) [13.0; 418.0]	55.5 (39.0) [17.0 429.0]
Amylase,	Ú/L	·
Week 0	63.9 (31.1) [13.0; 256.0]	62.2 (31.6) [11.0; 225.0]
Week 12	72.3 (37.7) [20.0; 291.0]	63.3 (31.2) [20.0; 201.0]
Week 26	70.1 (36.8) [23.0; 241.0]	61.2 (26.3) [13.0; 176.0]
	· · · · · · · · · · ·	· · · · · · · · · · ·

Values are mean (standard deviation) [min; max range]. N, number of subjects. Data are based on the SAS with LOCF. Met, metformin, GLP-1RA, glucagon-like peptide-1 receptor agonist; IDegLira, insulin degludec/liraglutide combination; LOCF, last observation carried forward; SAS; safety analysis set.

Supplementary Table 6: Patient-reported outcomes

Score	IDegLira (<i>n</i> = 291) Observed score at EOT	Unchanged GLP-1RA (<i>n</i> = 146) Observed score at EOT	IDegLira (<i>n</i> = 290) Observed change from baseline	Unchanged GLP-1RA (<i>n</i> = 146) Observed change from baseline	Estimated treatment contrast [95% CI] ANCOVA analysis IDegLira – GLP-1RA	
TRIM-D			[
Total score	82.3 ± 11.9	78.1 ± 13.9	8.7 ± 12.0	3.1 ± 12.2	5.0 [2.9, 7.2]; p < 0.001	
Treatment burden	81.2 ± 15.9	76.6 ± 18.0	10.8 ± 18.8	5.7 ± 19.3	5.0 [1.9; 8.0]; p = 0.002	
Daily life	84.5 ± 16.6	81.7 ± 18.7	6.3 ± 18.4	0.8 ± 18.2	3.7 [0.5; 6.8]; <i>p</i> = 0.022	
Diabetes management	72.0 ± 18.5	67.2 ± 20.2	10.9 ± 21.3	4.1 ± 19.8	5.7 [2.2; 9.2]; <i>p</i> = 0.002	

Compliance	87.2 ± 14.0	84.4 ± 16.9	8.9 ± 17.3	4.3 ± 15.9	3.5 [0.8; 6.2]; <i>p</i> = 0.010					
Psychological health	85.9 ± 14.8	80.5 ± 18.4	7.3 ± 14.7	1.4 ± 16.5	5.4 [2.7; 8.1]; <i>p</i> < 0.001					
DTSQs	DTSQs									
Treatment satisfaction total score	32.5 ± 4.2	30.7 ± 5.9	3.1 ± 5.6	1.1 ± 5.0	2.0 [1.1, 2.8]; <i>p</i> < 0.001					
Hyperglycemia	1.5 ± 1.6	2.5 ± 2.0	-1.8 ± 2.1	-0.6 ± 1.9	-1.0 [-1.4, -0.7]; p < 0.001					
Hypoglycemia	1.1 ± 1.5	0.7 ± 1.4	0.2 ± 1.7	-0.1 ± 1.5	0.4 [0.1, 0.6]; <i>p</i> = 0.006					

Data are observed patient-reported outcome scores at 26 weeks, changes from baseline (LOCF), and estimated treatment contrast. Data are mean ± standard deviation unless otherwise indicated. TRIM-D: higher score indicates a better health state. DTSQs: higher scores indicate higher satisfaction; DTSQ hyperglycemia and hypoglycemia: higher scores indicate higher perceived frequency.

ANCOVA, analysis of covariance; CI, confidence interval; DTSQs, diabetes treatment satisfaction questionnaire status; EOT, end-of-trial; GLP-1RA, glucagon-like peptide-1 receptor agonist; IDegLira, insulin degludec/liraglutide combination; LOCF, last observation carried forward; TRIM-D, treatment-related impact measure–diabetes.